Angiogenex is Pharmaceuticals in United States that focus on macular degeneration business. They cover business area such as AngioGenex Inc, commercialization, vascular disease, many form, cancer, macular degeneration, its lead drug candidate, several other proprietary small molecule, specific activity, various animal model, Id-inhibitor drug.
-
Macular Degeneration
-
425 Madison Avenue
Suite 902
New York, NY 10017
United States
Private
AngioGenex Inccommercializationvascular diseasemany formcancermacular degenerationits lead drug candidateseveral other proprietary small moleculespecific activityvarious animal modelId-inhibitor drug
* We use standard office opening hours in near Angiogenex's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Angiogenex is Pharmaceuticals business from United States that founded in - ( years old in ), Angiogenex business is focusing on Macular Degeneration.
Angiogenex headquarter office and corporate office address is located in 425 Madison Avenue Suite 902 New York, NY 10017 United States.
Angiogenex was founded in United States.
In , Angiogenex is currently focus on macular degeneration sector.
Above is snippet of Google Trends for "macular degeneration" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Angiogenex, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
